Skip to search formSkip to main contentSkip to account menu

FCE 28260

Known as: FCE-28260 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

5-alpha Reductase InhibitorsAndrostenesAzasteroids
PNU 156765

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
Effect of the 5α-Reductase Inhibitor PNU 156765, Alone or in Combination with Flutamide, in the Dunning R3327 Prostatic Carcinoma Model in Rats
The efficacy of treatment with the 5α-reductase inhibitor PNU 156765 (FCE 28260) was investigated in the Dunning R3327 prostatic… 
1996
1996
FCE 28260, a new 5 alpha-reductase inhibitor: in vitro and in vivo effects.
FCE 28260 is a novel inhibitor of 5 alpha-reductase (5 alpha R), the enzyme responsible for the conversion of testosterone (T) to… 
1994
1994
Novel aromatase and 5 alpha-reductase inhibitors.
Inhibitors of aromatase and 5 alpha-reductase may be of use for the therapy of postmenopausal breast cancer and benign prostatic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)